Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
J Phys Chem Lett ; 7(24): 4957-4961, 2016 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-27973867

RESUMO

Hyperconjugative interaction was demonstrated to play a vital role in the photochemistry of 4-aryl-1,1-dicyano-1-butenes. Thus a simple substituent on the benzylic position effectively induced a new photoreactivity to afford an allylic rearrangement product that is not obtained for the parent substrate. The natural bond orbital analysis was employed to reveal the enhanced relative contributions of hyperconjugation in the excited state, which dramatically alter the photochemical outcomes not only by reducing the strength of the allylic/benzylic bond but more crucially by affecting the conformer distribution.

2.
Org Lett ; 16(18): 4888-91, 2014 Sep 19.
Artigo em Inglês | MEDLINE | ID: mdl-25207472

RESUMO

Solvent, temperature, and excitation wavelength significantly affected the photochemical outcomes of a naphthalene-dicyanoethene system tethered by different number (n) of methylene groups (1-3). The effect of irradiation wavelength was almost negligible for 2a but pronounced for 3a. The temperature dependence and theoretical calculations indicated the diversity of exciplex conformations, an ensemble of which can be effectively altered by changing excitation wavelength to eventually switch the regioselectivity of photoreactions.

3.
Gan To Kagaku Ryoho ; 38(12): 1998-2001, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22202264

RESUMO

Pseudomyxoma peritonei (PMP) is characterized by mucinous ascites and implants throughout the peritoneal cavity. The tumor rarely involves retroperitoneum. We present a patient of PMP with retroperitoneal presentation and spontaneous development of a skin fistula. There had been only 7 such cases reported.


Assuntos
Fístula Cutânea/complicações , Neoplasias Peritoneais/cirurgia , Pseudomixoma Peritoneal/cirurgia , Feminino , Humanos , Pessoa de Meia-Idade , Invasividade Neoplásica , Neoplasias Peritoneais/complicações , Neoplasias Peritoneais/patologia , Pseudomixoma Peritoneal/complicações , Pseudomixoma Peritoneal/patologia
4.
Gan To Kagaku Ryoho ; 38(12): 2060-4, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22202284

RESUMO

PURPOSE: To evaluate the utility of CT of peritoneal carcinomatosis (PC) by comparing preoperative radiological and intraoperative peritoneal cancer index (PCI) scores. MATERIAL AND METHOD: This study collected 76 patients of PC from different disease origins. The sensitivity, specificity and accuracy were calculated in each of the abdominopelvic region, and by tumor histologic type. RESULT: An overall sensitivity of CT was 69%. The detection rate was highest in appendix and lowest in stomach group( 84% and 47%, respectively) by the origin of primary disease. There was a lower detection rate (59% vs 79%, p=0.001), and a higher underestimation rate (29% vs 21%, p<0.05) of small bowel lesion compared with overall abdomino-pelvic region. CT predicted an individual regional PCI score accurately in 65%, underestimated in 24%, and overestimated in 11%. CT detection rate in small tumor (<0.5 cm) was 29%, and increased to 97% with nodules size exceeding 5 cm. CT significantly underestimated the clinical PCI value in overall. CONCLUSION: The sensitivity of CT in detecting PC was influenced by histologic type, tumor location and size. CT underestimated the clinical PCI score in PC patient.


Assuntos
Carcinoma/diagnóstico por imagem , Neoplasias Peritoneais/diagnóstico por imagem , Tomografia Computadorizada por Raios X/métodos , Adulto , Idoso , Carcinoma/cirurgia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Peritoneais/cirurgia
5.
J Surg Oncol ; 100(4): 311-6, 2009 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-19697437

RESUMO

There is no standard treatment for peritoneal carcinomatosis (PC) from gastric cancer. New bidirectional chemotherapy (neoadjuvant intraperitoneal-systemic chemotherapy protocol (NIPS)) was developed. The aim of the present study was to assess the safety and efficacy of NIPS and to show the selection for cytoreductive surgery on PC from gastric cancer. Seventy-nine patients with PC from gastric cancer were treated with NIPS. A peritoneal port system was introduced into the abdominal cavity. The peritoneal wash cytological examination through a port was done before and after NIPS. The patients were treated with oral TS-1 twice a daily for 21 days, followed by a 1-week rest. On day 1, 8, and 15 from the start of oral TS-1 administration, 30 mg/m(2) of Docetaxel and 30 mg/m(2) of cisplatinum with 500 ml of saline were introduced into the peritoneal cavity through the port. A median course of oral TS-1 was 2.1 course and a median time of IP chemoterapy was 5.8. Peritoneal free cancer cells (PFCCs) had been detected in 65 (82.2%) patients before NIPS, and the positive cytology changed to be negative in 41 (63.0%) patients after NIPS. After NIPS, 41 patients underwent laparotomy, and complete cytoreduction was done in 32 (78%) patients. Complete cytoreduction was done in 27 (51.9%) of 52 patients with negative cytology but in only 4 (14.8%) of 27 patients with positive cytology (P < 0.001). Patients with negative cytology after NIPS survived significantly longer than those with positive cytology. The adverse effects after NIPS were mild and there was no treatment-related deaths. The grade 3/4 hematological adverse effects were found in 2 (2.6%) patients. Grade 3 renal toxicity and port site infection was found in three patients, respectively. NIPS using a port system is a safe and effective treatment for PC. Peritoneal wash cytology through a port system is a good indicator to select the patients to perform cytoreductive surgery.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Quimioterapia do Câncer por Perfusão Regional , Recidiva Local de Neoplasia/tratamento farmacológico , Neoplasias Peritoneais/tratamento farmacológico , Neoplasias Gástricas/tratamento farmacológico , Adulto , Idoso , Cisplatino/administração & dosagem , Terapia Combinada , Docetaxel , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/patologia , Recidiva Local de Neoplasia/cirurgia , Estadiamento de Neoplasias , Seleção de Pacientes , Neoplasias Peritoneais/secundário , Neoplasias Peritoneais/cirurgia , Prognóstico , Neoplasias Gástricas/patologia , Neoplasias Gástricas/cirurgia , Taxa de Sobrevida , Taxoides/administração & dosagem
6.
Breast Cancer ; 16(2): 141-6, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-18769994

RESUMO

Lymphocytic mastopathy is a benign breast disease characterized by dense fibrosis, lobular atrophy, and aggregates of lymphocytes in a periductal and perivascular distribution. The condition affects young to middle-aged women and frequently shows an association with diabetes mellitus or autoimmune disorders. Here, we report a case of the disease clinically and radiologically mimicking primary breast neoplasms. The patient was a 50-year-old woman without diabetes who presented with two firm lumps in her right breast. Breast imaging findings from mammography, ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI), respectively, revealed an abnormal appearance suspicious of malignancy. A core-needle biopsy specimen showed atypical accumulation of lymphoid cells, which was not easy to differentiate from primary breast lymphomas. Moreover, (18)fluorodeoxyglucose positron emission tomography (FDG-PET) examination detected abnormal uptake in the same lesions. Histological examination of a surgically obtained specimen showed characteristic appearance of lymphocytic mastopathy, which predominantly consisted of B-lymphocytes. In our case, it was difficult to distinguish this entity from breast cancer or low-grade B-cell lymphoma without surgical biopsy.


Assuntos
Neoplasias da Mama/diagnóstico , Linfócitos/patologia , Linfoma/diagnóstico , Mastite/diagnóstico , Neoplasias da Mama/cirurgia , Diagnóstico Diferencial , Feminino , Fluordesoxiglucose F18 , Humanos , Linfoma/cirurgia , Imageamento por Ressonância Magnética , Mamografia , Mastite/cirurgia , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Tomografia por Emissão de Pósitrons , Prognóstico , Compostos Radiofarmacêuticos , Tomografia Computadorizada por Raios X , Ultrassonografia Mamária
7.
Int J Clin Oncol ; 13(2): 132-7, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18463957

RESUMO

BACKGROUND: The survival of patients with advanced gastric cancer after D2 dissection is still poor. Asian surgeons have proposed a more radical lymph node dissection, designated as D4 dissection, where paraaortic lymph nodes are removed in combination with D2 dissection. To evaluate the survival benefit of D4 dissection, a multi-institutional randomized trial of D2 vs D4 gastrectomy was conducted. METHODS: Patients enrolled in the study had potentially curable gastric adenocarcinoma at an advanced stage. Patients were randomized to undergo either D2 or D4 gastrectomy. RESULTS: Two hundred and ninety-three patients were registered and 269 patients were eligible; 135 patients were allocated to the D2 group and 134 to the D4 group. Five-year survival was 52.6% after D2 surgery and 55.0% after D4 gastrectomy. There was no significant difference in survival between the D2 and D4 groups (chi(2) = 0.064; P = 0.801). Hospital deaths occurred in 1 patients (0.7%) in the D2 group and 5 in the D4 group D4 gastrectomy is a more risky surgery than D2 dissection. Seven patients (5.2%) in the D2 and 15 (11.2%) in the D4 group died of causes other than gastric cancer recurrence. Sixty-three patients (46.7%) in the D2 group and 52 (38.8%) in the D4 group had disease recurrence. CONCLUSION: Prophylactic D4 dissection is not recommended for patients with potentially curable advanced gastric cancer.


Assuntos
Adenocarcinoma/cirurgia , Gastrectomia/métodos , Excisão de Linfonodo/métodos , Neoplasias Gástricas/cirurgia , Adenocarcinoma/mortalidade , Adenocarcinoma/patologia , Idoso , Aorta , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Gástricas/mortalidade , Neoplasias Gástricas/patologia , Análise de Sobrevida
8.
Nihon Shokakibyo Gakkai Zasshi ; 104(12): 1745-51, 2007 Dec.
Artigo em Japonês | MEDLINE | ID: mdl-18057852

RESUMO

A 69-year-old man complaining of enlarged cervical mass, appetite loss and lower abdominal pain was found to have abdominal tumors in heaps forming a large mass around the retroperitoneum. The biopsy specimen in the cervical mass showed undifferentiated carcinoma with neuroendocrine feature. This malignancy followed a poorly aggressive course and caused death in only 24 hospital days. The disease was diagnosed as undifferentiated neuroblastoma arising in the retroperitoneum by autopsy with appropriate immunohistochemical studies. Adult neuroblastoma in the peritoneum is rare and our case showed a aggressive behavior and unfortunate outcome.


Assuntos
Neuroblastoma/patologia , Neoplasias Retroperitoneais/patologia , Idoso , Progressão da Doença , Humanos , Masculino
9.
Hepatogastroenterology ; 50(53): 1716-9, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14571825

RESUMO

BACKGROUND/AIMS: Twenty-one patients with primary stage IV gastric cancer were treated with a wide-spectrum regimen, designated as FEPMTX therapy to establish an effective salvage chemotherapy. METHODOLOGY: FEPMTX therapy consisted of 5-fluorouracil and the triple biochemical modulators in addition to epirubicin. The schedule comprised 3 days continuous administration of 5-fluorouracil (350 mg/m2/day) and; methotrexate (MTX; 35 mg/m2) on day 1, calcium leucovorin (LV; 30 mg/m2) on day 2 and 3, cisplatin (CDDP; 30 mg/m2) and epirubicin (20 mg/m2) on day 3 every 2 weeks in principle. RESULTS: Eleven partial responses, five no changes and five progressive diseases were obtained, and the response rate was 52%. Ten patients (partial response 7, no change 2, progressive disease 1) received gastrectomy (resectability rate 48%). The survival of responders was significantly longer than that of non-responders (median survival time, 356 days vs. 152 days) while there was no significant prolongation by resection of the primary lesion. Adverse effects such as myelosuppression, anorexia and fatigue sometimes occurred, but were mild and the regimen was well tolerated by all the patients. CONCLUSIONS: FEPMTX is thought to be an effective regimen for neoadjuvant chemotherapy with longer survival and little toxicity for patients with high-grade advanced gastric cancer.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Terapia de Salvação , Neoplasias Gástricas/tratamento farmacológico , Adulto , Idoso , Quimioterapia Adjuvante , Cisplatino/administração & dosagem , Epirubicina/administração & dosagem , Feminino , Fluoruracila/administração & dosagem , Gastrectomia , Humanos , Leucovorina/administração & dosagem , Masculino , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Neoplasias Gástricas/mortalidade , Neoplasias Gástricas/cirurgia , Análise de Sobrevida
10.
Gan To Kagaku Ryoho ; 29(12): 2178-83, 2002 Nov.
Artigo em Japonês | MEDLINE | ID: mdl-12484031

RESUMO

An aggressive approach to peritoneal dissemination involves peritonectomy procedures combined with preoperative intraperitoneal chemotherapy, intraoperative chemo-hyperthermia, and postoperative systemic chemotherapy. We have been performing multimodal therapy consisting of peritonectomy plus perioperative chemotherapy for the treatment of patients with peritoneal dissemination. Fifty-seven patients with established peritoneal dissemination from gastric cancer (n = 32), colon cancer (n = 17), ovarian cancer (n = 7), and mesothelioma (n = 1) have been treated with peritonectomy and intraoperative chemo-hyperthermia. Five-year survival rates of patients with gastric and colon cancer were 18% and 38%, respectively. Among various clinical factors, complete tumor resection was the most significant prognostic factor, and the prognosis of patients who underwent complete cytoreduction was significantly better than those who received incomplete cytoreduction. A multimodal therapy consisting of perioperative chemotherapy and peritonectomy with complete cytoreduction may be the most powerful method to treat patients with established peritoneal dissemination.


Assuntos
Neoplasias Peritoneais/terapia , Peritônio/cirurgia , Neoplasias do Colo/patologia , Neoplasias do Colo/terapia , Terapia Combinada , Feminino , Humanos , Hipertermia Induzida , Mesotelioma/patologia , Mesotelioma/terapia , Neoplasias Ovarianas/patologia , Neoplasias Ovarianas/terapia , Neoplasias Peritoneais/tratamento farmacológico , Neoplasias Peritoneais/secundário , Neoplasias Gástricas/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...